SFRP2 and melanoma: Pro-angiogenic data were also be obtained from in vivo mouse models, in which melanoma tumors treated with recombinant SFRP2 showed enhanced angiogenesis, which could be reversed by the addition of an anti-SFRP2 antibody [44].